



- Approved by the FDA in April 2020
- First drug for pediatric neurofibromas
- Treatment of children ages 2-18 years with neurofibromatosis type I (NF1)
- Selective inhibitor of mitogen-activated protein kinase kinase (MAPK kinase, MEK, MAP2K, and MAPKK)



Best percentage change in target PN volume is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction.

